X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS VENUS REMEDIES DR. DATSONS LABS/
VENUS REMEDIES
 
P/E (TTM) x -10.9 -4.8 - View Chart
P/BV x 0.2 0.2 91.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   VENUS REMEDIES
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
VENUS REMEDIES
Mar-18
DR. DATSONS LABS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs126126 99.8%   
Low Rs3161 50.6%   
Sales per share (Unadj.) Rs133.0301.8 44.1%  
Earnings per share (Unadj.) Rs0.2-24.9 -0.6%  
Cash flow per share (Unadj.) Rs6.62.5 259.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.8293.3 43.9%  
Shares outstanding (eoy) m31.6612.34 256.6%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.60.3 189.9%   
Avg P/E ratio x516.1-3.8 -13,728.5%  
P/CF ratio (eoy) x11.836.7 32.2%  
Price / Book Value ratio x0.60.3 190.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,4771,154 214.7%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m56393 14.2%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m4,2113,724 113.1%  
Other income Rs m7923 349.8%   
Total revenues Rs m4,2893,747 114.5%   
Gross profit Rs m569395 144.0%  
Depreciation Rs m204338 60.4%   
Interest Rs m430354 121.4%   
Profit before tax Rs m13-275 -4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m632 19.3%   
Profit after tax Rs m5-307 -1.6%  
Gross profit margin %13.510.6 127.4%  
Effective tax rate %48.0-11.5 -418.5%   
Net profit margin %0.1-8.2 -1.4%  
BALANCE SHEET DATA
Current assets Rs m6,8522,638 259.8%   
Current liabilities Rs m6,7112,305 291.2%   
Net working cap to sales %3.38.9 37.4%  
Current ratio x1.01.1 89.2%  
Inventory Days Days161135 118.8%  
Debtors Days Days31846 687.4%  
Net fixed assets Rs m3,6734,871 75.4%   
Share capital Rs m317123 256.6%   
"Free" reserves Rs m3,7613,496 107.6%   
Net worth Rs m4,0783,619 112.7%   
Long term debt Rs m1,6711,374 121.6%   
Total assets Rs m12,6337,509 168.2%  
Interest coverage x1.00.2 461.7%   
Debt to equity ratio x0.40.4 107.9%  
Sales to assets ratio x0.30.5 67.2%   
Return on assets %3.40.6 545.5%  
Return on equity %0.1-8.5 -1.4%  
Return on capital %7.71.6 485.0%  
Exports to sales %22.90-   
Imports to sales %14.313.9 103.1%   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602517 116.5%   
Fx inflow Rs m9640-   
Fx outflow Rs m607517 117.5%   
Net fx Rs m357-517 -69.1%   
CASH FLOW
From Operations Rs m1,345514 261.4%  
From Investments Rs m-2,256-123 1,832.3%  
From Financial Activity Rs m-1,200-387 309.9%  
Net Cashflow Rs m-2,1114 -50,254.8%  

Share Holding

Indian Promoters % 4.5 32.9 13.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 1.4 0.6 232.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 66.4 141.7%  
Shareholders   20,807 20,121 103.4%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS